肝硬化并发门静脉血栓患者临床特征及其危险因素分析

doi:10.3969/j.issn.1672-5069.2020.03.025

Abstract

Abstract: Objective The aim of this study was to analyze the clinical characteristics and risk factors of portal vein thrombosis (PVT) in patients with liver cirrhosis (LC). Methods A retrospective analysis was made on 160 patients with LC admitted to our Department in our hospital from February 2015 through February 2019. The clinical symptoms, laboratory indexes and general data of patients were collected. The multivariate Logistic analysis was applied to evaluate the risk factors of PVT. Results The incidence of abdominal pain, ascites and gastrointestinal hemorrhage, and the platelet (PLT) counts and white blood cell (WBC) counts in 80 patients with PVT were significantly higher than those in 80 patients without PVT; the multivariate Logistic analysis showed that the PLT counts, diabetes and splenectomy were the independent risk factors for PVT in patients with LC (P<0.05). Conclusion The ascites, gastrointestinal hemorrhage and liver dysfunction are the main clinical manifestation in patients with LC and PVT, and the PLT counts, diabetes and splenectomy are the main independent risk factors for portal vein thrombosis.

Key words: Liver cirrhosis, Portal vein thrombosis, Platelets, Diabetes mellitus, Splenectomy, Risk factors

Rinat·Kirim, Turganaili·Aj, Shao Yinmei.. Clinical characteristics and risk factors of portal vein thrombosisin patients with liver cirrhosis[J]. Journal of Practical Hepatology, 2020, 23(3): 401-404.

References

[1] Katsanos K, Al-Lamki SA, Parthipun A,et al. Peripheral stent thrombosis leading to acute limb ischemia and major amputation: Incidence and risk factors in the aortoiliac and femoropopliteal arteries. Cardiovasc Intervent Radiol, 2017, 40(3): 351-359.
[2] Chen J, Wu X, Keesee J, et al. Limited resuscitation with fresh or stored whole blood corrects cardiovascular and metabolic function in a rat model of polytrauma and hemorrhage. Shock, 2017, 47(2): 208-216.
[3] 章燕虹, 李游, 陈龙, 等. 2890例住院的肝硬化患者病因和并发症分析. 实用肝脏病杂志, 2018, 21(3): 344-347.
[4] Li G, Huang Y, Tang S, et al. A single-center retrospective study: Clinical features of different types of Budd-Chiari syndrome in Chinese patients in the Hubei area. Vascular, 2018, 26(1): 80-89.
[5] Thornburg B, Desai K, Hickey R, et al. Portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: Technical considerations. Tech Vasc Interv Radiol, 2016, 19(1): 52-60.
[6] Gastaca M, Prieto M, Palomares I, et al. Significance of measured intraoperative portal vein flows after thrombendvenectomy in deceased donor liver transplantations with portal vein thrombosis. Liver Transpl, 2018, 24(4): 565-566.
[7] Jiang TT, Luo XP, Sun JM, et al. Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy vs transjugular intrahepatic portosystemic shunt in patients with cirrhosis and acute portal vein thrombosis. World J Gastroenterol, 2017, 23(41): 7470-7477.
[8] Zuo C, Chumbalkar V, Ells PF, et al. Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies. Hepatol Int, 2017, 11(5): 452-460.
[9] Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and meta-analysis. Gastroenterology, 2017, 153(2): 480-487.
[10] Sahin I, Reagan JL, Niroula R, et al. Refractoriness to red blood cell transfusion therapy due to hypersplenism. Transfusion, 2018, 58(11): 2513-2516.
[11] Wang P, Li Z, Ren S, et al. Spleen regulates hematopoietic stem/progenitor cell functions through regulation of EGF in cirrhotic hypersplenism. Dig Dis Sci, 2018, 63(7): 1860-1867.
[12] Chouhan MD, Mookerjee RP, Bainbridge A, et al. Caval subtraction 2D phase-contrast MRI to measure total liver and hepatic arterial blood flow: Proof-of-principle, correlation with portal hypertension severity and validation in patients with chronic liver disease. Invest Radiol, 2017, 52(3): 170-176.
[13] Guipaud O, Jaillet C, Clément-Colmou K, et al. The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy. Br J Radiol, 2018, 91(1089): 20170762.
[14] Do J, Gwak J, Rho JJ, et al. Aqueous extract of taegeuk ginseng inhibits platelet aggregation and thrombus formation. J Med Food, 2018, 21(11): 1137-1144.
[15] Vito CD, Hadi LA, Navone SE, et al. Platelet-derived sphingosine-1-phosphate and inflammation: From basic mechanisms to clinical implications. Platelets, 2016, 27(5): 393-401.
[16] van Santen DK, Schim van der Loeff MF, Cartier van Dissel J, et al. High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands. Eur J Gastroenterol Hepatol, 2018, 30(10): 1168-1176.
[17] Williams MJ, Hayes P. Improving the management of gastrointestinal bleeding in patients with cirrhosis. Expert Rev Gastroenterol Hepatol, 2016, 10(4): 505-515.
[18] 王晓赵文霞.夜间加餐干预可促进失代偿期肝硬化患者肝功能恢复.实用肝脏病杂志, 2018, 21(1): 112-113.
[19] Pose E, Cardenas A. Translating our current understanding of ascites management into new therapies for patients with cirrhosis and fluid retention. Dig Dis, 2017, 35(4): 402-410.
[20] 郑俊福, 丁惠国.肝硬化急性食管胃静脉曲张出血临床救治新理念.实用肝脏病杂志, 2016, 19(5): 516-518.
[21] Khishfe BF, Sankovsky A, Nasr I. Idiopathic ovarian vein thrombosis: a rare cause of abdominal pain. Am J Emerg Med, 2016, 34(5): 935.
[22] Klinger C, Riecken B, Schmidt A, et al. Transjugular portal vein recanalization with creation of intrahepatic portosystemic shunt (PVR-TIPS) in patients with chronic non-cirrhotic, non-malignant portal vein thrombosis. Z Gastroenterol, 2018, 56(3): 221-237.
[23] Geng WZM, Fuller M, Osborne B, et al. The value of the erect abdominal radiograph for the diagnosis of mechanical bowel obstruction and paralytic ileus in adults presenting with acute abdominal pain. J Med Radiat Sci, 2018, 65(4): 259-266.
[24] Ruggeri P, Lo Bello F, Nucera F, et al. Hereditary hyperhomocysteinemia associated with nephrotic syndrome complicated by artery thrombosis and chronic thromboembolic pulmonary hypertension: A case report. Monaldi Arch Chest Dis, 2017, 87(3): 880.
[25] Yue-Meng W, Li YH, Wu HM, et al. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt: risk factors, warfarin efficacy, and clinical outcomes. Clin Appl Thromb Hemost, 2018, 24(3): 462-470.
[26] Yuan J, Xu GM. Early and late stent thrombosis in patients with versus without diabetes mellitus following percutaneous coronary intervention with drug-eluting stents: A systematic review and meta-analysis. Am J Cardiovasc Drugs, 2018, 18(6): 483-492.
[27] Wang H, Wang Z, Tang Q. Reduced expression of microRNA-199a-3p is associated with vascular endothelial cell injury induced by type 2 diabetes mellitus. Exp Ther Med, 2018, 16(4): 3639-3645.
[28] Lehmann M, Schoeman RM, Krohl PJ, et al. Platelets drive thrombus propagation in a hematocrit and glycoprotein vi-dependent manner in an in vitro venous thrombosis model. Arterioscler Thromb Vasc Biol, 2018, 38(5): 1052-1062.
[29] Sauter RJ, Sauter M, Obrich M, et al. Anaphylatoxin receptor C3aR contributes to platelet function, thrombus formation and In vivo haemostasis. Thromb Haemost, 2019, 119(1): 179-182.

Clinical characteristics and risk factors of portal vein thrombosisin patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Ming, Pu Lin, Xiong Haofeng, et al.. Comparison of KDIGO and ICA criteria in diagnosing acute kidney injury in critically ill cirrhotic patients [J]. Journal of Practical Hepatology, 2020, 23(3): 392-396.
[2]	Kang Xiao, Yu Li, Wang Lei, et al.. Value of endoscopic ultrasonography in diagnosis of esophagogastric varices in patients with hepatitisB liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(3): 397-400.
[3]	Jia Chen, Zhang Tao, Wang Hao, et al. Efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(2): 203-206.
[4]	Liu Jiguo, Dou Cuiyun , Cheng Guangling. Changes of blood glycosylated hemoglobin and thyroid hormone levels in patients with NAFLD complicated by T2DM [J]. Journal of Practical Hepatology, 2020, 23(2): 207-210.
[5]	Zhang Huiyong, Wu Xiuxin, Xu Chengrun. Clinical efficacy of ultrafiltration, concentration and reinfusion of ascites and alprostadil and terlipressin combination in treatment of patients with cirrhosis complicated by refractory ascites [J]. Journal of Practical Hepatology, 2020, 23(2): 244-247.
[6]	A Sigen, Xia Yijun, Wu Huijun, et al. Efficacy of laparoscopic portal-azygos vein devascularization and splenectomy in treatment of patients with cirrhotic portal hypertension [J]. Journal of Practical Hepatology, 2020, 23(2): 248-251.
[7]	Hu Xing, Meng Fankun, Han Jing, et al. Clinical value of echocardiography in evaluating cardiac structure and function in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(2): 252-255.
[8]	Xing Lekang, Deng Yongdong, Yao Liqiong, et al. Changes of intestinal flora in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(2): 256-259.
[9]	Xu Xiaoyuan. Highlights of newly released guideline for diagnosis and treatment of liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(1): 4-6.
[10]	Chen Lili, Fu Maoxiong, Meng Xubiao, et al. Clinical value of fasting C-peptide in assessing the progression of liver fibrosis in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2020, 23(1): 38-41.
[11]	Mao Chongshan, Yin Hui, Xiao Erhui, et al. Effects of fenofibrate on blood lipids, vascular endothelial functions and liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(1): 50-53.
[12]	Wang Jianhui, Guo Hongdan, Kong Jingjing, et al. Clinical characteristics and risk factors ofdrug-induced liver injury caused by antituberculosis therapy [J]. Journal of Practical Hepatology, 2020, 23(1): 58-61.
[13]	Yang Xiaoling, Zhang Sumei. Application of SGA, MNA and NRS2002 in nutritional assessment of patients withdecompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(1): 70-73.
[14]	Wang Jingjing, Li Chuntao, Zhou Weizhen. Urineretinol binding protein levels in patients with hepatitis B-induced decompensated liver cirrhosis as the index for acute kidney injury [J]. Journal of Practical Hepatology, 2020, 23(1): 74-77.
[15]	Yang Huiling, Liu Xiaojing, He Yingli, et al. Clinical characteristicsof and risk factors for nosocomial infections in patients with hospitalized decompensated hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(1): 78-81.